Premotor Parkinson's disease: clinical features, detection, and prospects for treatment

Annals of Neurology
Andrew Siderowf, Matthew B Stern

Abstract

The period immediately before the onset of motor symptoms of Parkinson's disease (PD) often has a recognizable phenotype with features including autonomic dysfunction and impaired olfaction. Subclinical dopaminergic cell loss can also be detected at this time using molecular imaging techniques. A greater recognition of the features of premotor PD and improvements in screening technologies have opened the possibility of predictive testing for PD. In addition to molecular imaging of the dopamine system, screening tests that can potentially be used to identify the physiological abnormalities in premotor PD include olfactory testing, imaging of the sympathetic innervation of the heart, transcranial ultrasound, and genetic testing for mutations known to cause hereditary PD. All of these technologies have trade-offs as screening tests for accuracy, availability, and costs. Using these tests in combination may produce a more favorable combination of reasonable cost and accuracy than using any single test alone. Ultimately, the value of screening for PD depends on development of neuroprotective treatments for PD that would create an imperative for early identification and treatment.

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Feb 1, 1987·American Journal of Medical Genetics·S KesslerH Mosbarger
Feb 1, 1987·American Journal of Medical Genetics·C MastromauroB Berkman
Feb 1, 1987·American Journal of Medical Genetics·D S MarkelJ B Penney
Dec 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·P K MorrishD J Brooks
Mar 1, 1995·Neurodegeneration : a Journal for Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration·R L DotyM B Stern
Jan 1, 1995·The Journal of Neuropsychiatry and Clinical Neurosciences·M A MenzaD J Brooks
Mar 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·G GlosserM Stern
Nov 1, 1993·The Journal of Nervous and Mental Disease·J P HubbleW C Koller
Feb 1, 1994·Neurology·M B SternH Hurtig
Jan 1, 1993·American Journal of Medical Genetics·K A Quaid, M Morris
Apr 1, 1993·Neurology·A AntoniniM Anliker
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·R PahwaW C Koller
Dec 17, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·E G GoneraM W Horstink
May 23, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·G PlazziE Lugaresi
Jan 29, 1999·Archives of Neurology·D J GelbS Gilman
Apr 6, 1999·Archives of Neurology·R C PetersenE Kokmen
May 20, 2000·JAMA : the Journal of the American Medical Association·G W RossL R White
May 29, 2000·The New England Journal of Medicine·C B LückingUNKNOWN European Consortium on Genetic Susceptibility in Parkinson's Disease
Aug 6, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·M ShibaW A Rocca
Dec 2, 2000·Brain : a Journal of Neurology·J M GrahamP D Griffiths
Dec 25, 2002·Neurobiology of Aging·Heiko BraakEva Braak

❮ Previous
Next ❯

Citations

Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong
Apr 14, 2011·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Nicole M GattoBeate Ritz
Aug 24, 2012·Neurology·Avner ThalerUNKNOWN LRRK2 Ashkenazi Jewish Consortium
Aug 19, 2011·Annals of Indian Academy of Neurology·Madhuri BehariGarima Shukla
Apr 3, 2016·The Journal of the Acoustical Society of America·François-Xavier BrajotVincent L Gracco
Sep 10, 2015·Behavioural Neurology·Cleo KritzingerMeike Kasten
Nov 12, 2014·Frontiers in Aging Neuroscience·Sandra E HasmannWalter Maetzler
Dec 22, 2012·International Journal of Epidemiology·Meike KastenChristine Klein
Apr 13, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony E Lang
Dec 3, 2016·Journal of the International Neuropsychological Society : JINS·Christine A Cooper, Lama M Chahine
Mar 25, 2015·Der Nervenarzt·M Synofzik, W Maetzler
Dec 15, 2012·Expert Review of Neurotherapeutics·Rizwan S Akhtar, Matthew B Stern
Dec 22, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Alberto BergarecheJosé Félix Martí-Massó
Apr 6, 2011·Current Opinion in Neurology·Lama M Chahine, Matthew B Stern
Apr 13, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony E Lang, Alberto J Espay
Nov 18, 2010·Expert Review of Molecular Diagnostics·George D MellickGerhard A Siebert
May 7, 2020·Movement Disorders Clinical Practice·Stephen D AugerAlastair J Noyce
Jul 22, 2019·Trends in Pharmacological Sciences·Manish D ParanjpeMarina Sirota

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Christopher H Hawkes
Archives of Neurology
Yuncheng WuJoseph Jankovic
Movement Disorders : Official Journal of the Movement Disorder Society
E G GoneraM W Horstink
Clinical Chemistry and Laboratory Medicine : CCLM
David P BreenRoger A Barker
© 2021 Meta ULC. All rights reserved